Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Pemetrexed, Etrumadenant, and Zimberelimab for the Treatment of Advanced or Metastatic Urothelial Carcinoma

Trial Status: closed to accrual

This phase II trial tests whether pemetrexed, etrumadenant, and zimberelimab works to shrink tumors in patients with urothelial cancer that has spread to other places in the body (advanced or metastatic). Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a certain substance in the body that may help cancer cells multiply. Etrumadenant may stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as zimberelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pemetrexed, etrumadenant, and zimberelimab may help to control urothelial cancer (bladder, urethra, and/or ureters) that has spread or cannot be controlled with surgery.